Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 08, 2026 07:00 ET | Source: Tisento Therapeutics Inc

Tisento Therapeutics Completes Enrollment in PRIZM, a Global Phase 2b Study of Zagociguat for the Treatment of MELAS

Tisento's global Phase 2b PRIZM study, which is evaluating zagociguat for the treatment of the rare mitochondrial disease MELAS, is fully enrolled
October 06, 2025 11:39 ET | Source: BPGbio

BPGbio Appoints Veteran Clinical and Commercial Leader Dr. Brian Berman as Interim Chief Medical Officer

Company strengthens its late-stage trials with enhanced clinical and commercial leadership for its BPM31510 programs
September 24, 2025 08:00 ET | Source: BPGbio

BPGbio Sponsors MitoAction Energy Walk at Boston’s Franklin Park Zoo on September 27th, 2025

BOSTON, Sept. 24, 2025 (GLOBE NEWSWIRE) -- BPGbio, Inc., a biology-first, AI-powered, clinical-stage biopharma focused on mitochondrial biology and protein homeostasis, today announced its...
June 18, 2025 07:00 ET | Source: BPGbio

BPGbio Announces Presentation of Preliminary Clinical Data of Investigational BPM31510 for Primary CoQ10 Deficiency

BPM31510 provides encouraging evidence of the potential for transformative benefit for a disease with high unmet need, supporting further development.The Company plans to seek guidance in Q3 2025 from...
May 28, 2025 07:00 ET | Source: BPGbio

BPGbio Presents Advances in Spatial Omics Technology and Targeted Protein Degradation Insights at ASMS 2025

BPGbio Presents Advances in Spatial Omics Technology and Targeted Protein Degradation Insights at ASMS 2025
April 25, 2025 07:00 ET | Source: BPGbio

BPGbio Highlights Groundbreaking Data on BPM31510 for Mitochondrial Diseases at the Inaugural Mitochondrial Transplantation and Next Generation Therapeutics Conference

BPGbio highlights groundbreaking data on BPM31510 illustrating it's therapeutic impact as a potential treatment for primary CoQ10 deficiency.
January 27, 2025 07:00 ET | Source: Tisento Therapeutics Inc

First Participant Dosed in Tisento Therapeutics’ Global Phase 2b PRIZM Study Evaluating Zagociguat for the Treatment of MELAS

The first patient has been dosed in Tisento's global Phase 2b PRIZM study investigating zagociguat in MELAS.
November 21, 2024 07:00 ET | Source: Khondrion

UMDF and Khondrion Announce The Mito Fund’s Investment in Khondrion to Support Development of One of the Most Advanced Drug Candidates for Primary Mitochondrial Disease

21 November 2024 – The United Mitochondrial Disease Foundation’s (UMDF) venture philanthropy arm, The Mito Fund, has invested in Khondrion, a Netherlands-based clinical stage biopharmaceutical company...
September 26, 2024 06:00 ET | Source: OMEICOS Therapeutics GmbH

OMEICOS Therapeutics Completes Enrollment of PMD-OPTION Study in Primary Mitochondrial Disease

Interim data confirms OMT-28’s strong safety profile in PMD patients, top-line data expected mid-2025 BERLIN, GERMANY, September 26, 2024 – OMEICOS, a biopharmaceutical company developing...
September 11, 2024 07:00 ET | Source: Khondrion

Khondrion appoints Jasper Levink as Chief Financial and Business Officer

Khondrion appoints Jasper Levink as Chief Financial and Business Officer NIJMEGEN, the Netherlands – 11 September 2024: Khondrion, a clinical stage biopharmaceutical company discovering and...